Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
Avex Life Sciences Corp
Apnimed Inc
Dermavant Sciences Inc
FemmePharma Global Healthcare Inc
Karu Therapeutics Inc
TheraVida Inc
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
(atomoxetine + oxybutynin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxybutynin + pilocarpine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(pilocarpine + tolterodine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AD-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVEX-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
Featured News & Press Releases
Oct 15, 2020: Avex Life Sciences announces positive results from proof of concept controlled phase 2 clinical trial evaluating Avex 2-73 (blarcamesine) in Parkinson’s disease dementia
Oct 07, 2020: Karu Therapeutics provides update on KarXT
Sep 17, 2020: Apnimed successfully completes phase 1 study in lead program for Obstructive Sleep Apnea
Sep 10, 2020: Avex Life Sciences announces completion of AVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome clinical trial
Aug 19, 2020: Avex Life Sciences announces commitment for Fincial Investment by Shake It Up Foundation for Parkinson’s Research for clinical trial of AVEX?2-73 (Blarcamesine) in patients with Parkinson’s disease
Aug 05, 2020: Avex Life Sciences receives TGA special access scheme approval for AVEX2-73 (blarcamesine) for Alzheimer’s disease patients
Aug 03, 2020: Karu Therapeutics announces topline data from phase 1b trial evaluating KarXT on experimentally induced pain in healthy volunteers
Jul 02, 2020: Avex starts dosing patients in Rett syndrome trial
Jul 01, 2020: Avex Life Sciences announces first patient dosed in EXCELLENCE Phase 2/3 clinical trial of AVEX?2-73 (Blarcamesine) in patients with Rett Syndrome
Jun 23, 2020: Karu Therapeutics announces positive outcome of end-of-phase 2 meeting with the FDA for KarXT for the treatment of acute psychosis in patients with schizophrenia
Jun 16, 2020: Avex Life Sciences announces exceeding of enrollment target for the AVEX 2-73 (blarcamesine) U.S. phase 2 Rett Syndrome clinical trial
Jun 04, 2020: Avex Life Sciences receives regulatory approval from Health Cada and UK MHRA expanding phase 2b/3 AVEX2-73 (blarcamesine) into multitiol clinical trial for Alzheimer’s disease
May 27, 2020: Karu Therapeutics to present additiol data from the phase 2 clinical trial of KarXT for the treatment of psychosis in patients with schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
Apr 23, 2020: Avex Life Sciences announces publication of clinical data for AVEX2-73 (blarcamesine) in Alzheimer’s Disease
Feb 24, 2020: Avex Life Sciences announces publication of foundatiol data for AVEX2-73 (blarcamesine) in multiple sclerosis (MS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Anavex Life Sciences Corp, H2 2020
Pipeline by Apnimed Inc, H2 2020
Pipeline by Dermavant Sciences Inc, H2 2020
Pipeline by FemmePharma Global Healthcare Inc, H2 2020
Pipeline by Karuna Therapeutics Inc, H2 2020
Pipeline by TheraVida Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020